Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) Can’t Be Less Risky. Short Interest Decreased

April 16, 2018 - By Jacob Falcon

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

The stock of Teva Pharmaceutical Industries Limited American DE (NYSE:TEVA) registered a decrease of 6.66% in short interest. TEVA’s total short interest was 65.70 million shares in April as published by FINRA. Its down 6.66% from 70.39 million shares, reported previously. With 16.65 million shares average volume, it will take short sellers 4 days to cover their TEVA’s short positions. The short interest to Teva Pharmaceutical Industries Limited American DE’s float is 6.98%.

The stock decreased 0.17% or $0.03 during the last trading session, reaching $18.02. About 2.75M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 16, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $18.32 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 26 analysts covering Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA), 6 have Buy rating, 7 Sell and 13 Hold. Therefore 23% are positive. Teva Pharmaceutical Industries Limited American Depositary Shares had 52 analyst reports since October 20, 2017 according to SRatingsIntel. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given on Thursday, January 11 by Goldman Sachs. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Buy” rating by Mizuho on Tuesday, January 9. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, February 15. Mizuho has “Buy” rating and $23.0 target. The stock has “Sell” rating by Leerink Swann on Friday, January 26. Credit Suisse upgraded the stock to “Neutral” rating in Friday, December 15 report. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by Gabelli on Friday, February 9. RBC Capital Markets maintained it with “Sell” rating and $11.0 target in Wednesday, November 29 report. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Wednesday, November 29. Mizuho has “Hold” rating and $16.0 target. The rating was maintained by Oppenheimer with “Hold” on Tuesday, January 23. Citigroup maintained it with “Neutral” rating and $13 target in Monday, November 13 report.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.